Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects
A Double-Blind, Placebo- and Positive-Controlled, Randomized, Partial 6-way Crossover Study to Investigate the Pharmacodynamics and Pharmacokinetics of CEP-26401 (5, 25, and 125 μg) Following Single-Dose Administration to Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Leiden, Netherlands
- Teva Investigational Site 38051
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is able to give legal informed consent and understand the requirements of the study and communicate with the investigator in the local spoken language.
- The subject is willing to comply with the study requirements (eg, all dietary, exercise, tobacco, and alcohol restrictions) and provide their written informed consent to participate in the study.
- The subject is a man or woman, 18 to 50 years of age, inclusive.
- The subject has a body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive.
- The subject has skin type I to IV (very light to olive).
- The subject is in a good health as determined by medical history, ECG, vital signs, physical examination, and clinical laboratory tests.
- Female subjects of childbearing potential must have a negative serum β-human chorionic gonadotropin (hCG) test (at screening) and check-in and be willing and able to use one of the protocol-specified double-barrier methods of birth control.
- The subject is able to complete the screening process within 4 weeks prior to study drug administration.
Exclusion Criteria:
- The subject has a cognitive performance outside of reference values at screening.
- The subject smokes, is a tobacco user, currently uses nicotine products.
- The subject has a known hypersensitivity to donepezil, modafinil, irdabisant, or one of the excipients, or has any significant food or drug allergies.
- The subject is a female who is pregnant or lactating.
- The subject has an intraocular pressure greater than 22 mm Hg.
- The subject is suffering from, or has a clinically significant history of one or more of the following: cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s), or a history of any illness that, in the opinion of the investigator, might pose additional risk to the subject by participation in the study or confound the results of the study.
The subject has a laboratory abnormality judged by the investigator as clinically significant, or measurements outside of the defined range
- Other exclusion criteria apply; please contact the investigator for more information.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CEP-26401 5 μg, 25 μg, 125 μg, placebo
Participants are dosed four times during this cross-over study.
This group takes three active interventions (CEP-26401 in each of the dose options: 5, 25 and 125 μg, and one dose that only contains the placebos.)
|
CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.
Other Names:
Placebos formulated to match each active drug
|
|
Experimental: CEP-26401 5 μg, 25 μg, placebo, donepezil
Participants are dosed four times during this cross-over study.
This group takes three active interventions (CEP-26401 at 5 and 25 μg, and donepezil at 10mg and one dose that only contains the placebos.)
|
CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.
Other Names:
Placebos formulated to match each active drug
Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated
Other Names:
|
|
Experimental: CEP-26401 5 μg, 125 μg, placebo, modafinil
Participants are dosed four times during this cross-over study.
This group takes three active interventions (CEP-26401 at 5 and 125 μg, and modafinil at 200mg) and one dose that only contains the placebos.)
|
CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.
Other Names:
Placebos formulated to match each active drug
modafinil 200 mg tablet, over-encapsulated
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Paired Associate Learning (PAL) Test
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Rapid Visual Information Processing (RVIP) Test
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Spatial Working Memory Test
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Stop Signal Task (SST)
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Adaptive tracking Test
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Body sway Test
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Leeds Sleep Evaluation Questionnaire (LSEQ)
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Leiden Maze Test (LMT)
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
n-Back Working Memory Test
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Polysomnography (PSG) Test
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Saccadic Eye Movements
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Single-Choice Reaction Time
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Smooth Pursuit Eye Movements
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
|
Visual Analog Scales (VAS)
Time Frame: Baseline to Hour 22
|
Factors ranging from 'not at all' to 'extremely' are used to quantify subjective drug effects
|
Baseline to Hour 22
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
area under the drug concentration-time curve (AUC0-t)
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
maximal observed plasma drug concentration (Cmax)
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
time to maximum observed plasma drug concentration (tmax)
Time Frame: Baseline to Hour 22
|
Baseline to Hour 22
|
|
Summary of participants with Adverse Events
Time Frame: From signing of the consent form to Day 30
|
From signing of the consent form to Day 30
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Neurocognitive Disorders
- Cognition Disorders
- Cognitive Dysfunction
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Central Nervous System Stimulants
- Nootropic Agents
- Cholinesterase Inhibitors
- Wakefulness-Promoting Agents
- Donepezil
- Modafinil
Other Study ID Numbers
Other Study ID Numbers
- C26401/1111
- 2013-001883-51 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.